摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(5-氨基-嘧啶-2-基)-乙酰胺 | 59690-85-6

中文名称
N-(5-氨基-嘧啶-2-基)-乙酰胺
中文别名
——
英文名称
N-(5-aminopyrimidin-2-yl)acetamide
英文别名
N-(5-Amino-pyrimidin-2-yl)-acetamid;2-acetamido-5-aminopyrimidine
N-(5-氨基-嘧啶-2-基)-乙酰胺化学式
CAS
59690-85-6
化学式
C6H8N4O
mdl
——
分子量
152.156
InChiKey
QNBQTWLRRGFOJV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -1.4
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.17
  • 拓扑面积:
    80.9
  • 氢给体数:
    2
  • 氢受体数:
    4

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Tozaki, Kagaku Kenkyusho Hokoku, 1951, vol. 27, p. 401; vgl. E I 24 231
    摘要:
    DOI:
  • 作为产物:
    描述:
    N-(5-nitropyrimidin-2-yl)acetamide 氢气甲醇 作用下, 以 甲醇 为溶剂, 反应 17.0h, 以to provide the desired compound as pale yellow needles (29, 520 mg, 100%)的产率得到N-(5-氨基-嘧啶-2-基)-乙酰胺
    参考文献:
    名称:
    COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR
    摘要:
    描述了对蛋白激酶活性有效的化合物,并提供了使用这些化合物治疗与蛋白激酶异常活性相关的疾病和病症的方法。
    公开号:
    US20140303187A1
点击查看最新优质反应信息

文献信息

  • Sulfonamido pyrimidines
    申请人:AMERICAN CYANAMID CO
    公开号:US02430439A1
    公开(公告)日:1947-11-04

    555,865. Sulphonamido pyrimidines. AMERICAN CYANAMID CO. March 8, 1941, Nos. 3174 and 3175. Convention dates, March 1, 1940 and Oct. 15, 1940. Samples furnished. [Class 2 (iii)] p-Substituted benzene-sulphonamido-pyrimidenes are made by reacting a benzene-sulphonyl halide, e.g. a chloride substituted in the para position by an amino group or a group convertible thereto by hydrolysis, reduction or by reaction with ammonia or an amine such as an acylamino, nitro, halogen or azo group, with an amino-pyrimidine. The products are of the general formula where R is a halogen, nitro, azo, amino or substituted amino group, e.g. alkylamino, arylamino, aralkylamino, acylamino or monoaldose amino, X is H, an alkyl group or a metal, Py is a pyrimidine substituted or unsubstituted and n is a small integer. The mono-aldose amino compounds are'made from the corresponding amino compounds by reaction with a mono aldose sugar such as galactose or glucose preferably in a solvent such as ethanol. Free hydrogen halide obtained during the reaction with a sulphonyl halide is removed by effecting the reaction in a basic medium, e.g. aqueous sodium hydroxide, triethylamine and pyridine and solvents, e.g. dioxane, acetone and benzene are specified. Alkali metal or heavy metal, e.g. gold, lead, copper and iron, salts of the products are also described. Examples describe the preparation of the following compounds by the above methods (1) 5-(N<;SP>;4<;/SP>;- acetylsulphanilamido) - 2, 4 - dihydroxy-, (2) 5 - (sulphanilamido) - 2, 4 - dihydroxy-, (3) 5 - (p - nitrobenzene sulphonamido) - 2, 4 - dihydroxy-, (4) 5 - (N<;SP>;4<;/SP>; -acetylsulphanil - - amido)-, (5) 5 - (sulphanilamido)-, (6) 4 - (p - nitrobenzenesulphonamido)-, (7) and (9) 4 - (sulphanilamido)-, (8) 4 - (N<;SP>;4<;/SP>; - acetyl - sulphanilamido)-, (10) 2 - (p - nitrobenzene - sulphonamido)-, (11) and (13) 2 - (sulphanil - amido)-, (12) 2 - (N<;SP>;4<;/SP>; - acetylsulphanilamido) -, (14) 4 - p - nitrobenzenesulphonamido 2 - methoxy-, (15) 4 - sulphanilamido - 2 - methoxy-, (16) 2 - (p - nitrobenzene - sulphon - amido) 4 - methoxy-, (17) 2 - sulphanilamido- 4 - methoxy-, (18) 2 - (p - nitrobenzene - sulphonamido) - 4, 6 - dimethyl-, (19) 2 - sulphanlamido - 4, 6 - dimethyl-, (20) 2 - N<;SP>;1<;/SP>; - methyl - sulphanilamido-, (21) 4 - p - chloro - benzene - sulphamido-, (this pyrimidine may be reacted with ammonia or amines, e.g. methylamine, aniline or benzyl amine to yield the corresponding substituted 4-N<;SP>;4<;/SP>; pyrimidine), (22) azobenzene - p -, p<;SP>;1<;/SP>; - (di - 2 - sulphon - amido)-, (23) 5 - (N<;SP>;4<;/SP>; - acetylsulphanilamido) - 2 - acetylamino-, (24) 5 - sulphanilamido - 2 - amino, (25) 5 - (p - nitrobenzenesulphonamido) - 2 - methoxy-, (26) 5 - sulphanilamido - 2. - methoxy-, (27) 2 - (N<;SP>;4<;/SP>; - acetylsulphanilamido) - 4 - ethoxy,- (28) 2 - sulphanilamido - 4 - ethoxy, (29) 2, 5 - di (p - nitrobenzene - sulphonamido)-, (30) 2, 5 - disulphanilamido-, (31) 2 - (p - nitrobenzene - sulphonamido) - 5 - chloro-, (32) 2 - sulphanilamido - 5 - chloro-, (33) sodium salt of 2 - sulphanilamido-, (34) copper salt of 2 - sulphanilamido-, (35) the glucose derivative of 2-sulphanilamido- and (36) 2-(N<;SP>;4<;/SP>;-benzylsulphanilamido)-pyrimidine. Examples (35) and (36) relate to two typical samples which have been furnished. The Specification as open to inspection under Sect. 91 states that in some cases the products may also be made by reacting a halogen substituted pyrimidine with an N<;SP>;4<;/SP>;-acylsulphanilamide in the presence of an alkali with subsequent hydrolysis of the acyl group. In examples (23) N<;SP>;4<;/SP>;-acetylsulphanilamide is treated with 2-chloro-4, 6-dimethylpyrimidine in the presence of potassium carbonate and copper powder to yield 2-N<;SP>;4<;/SP>;-acetylsulphanilamido-4, 6-dimethyl pyrimidine which is hydrolysed to the free amine, (24) 2-sulphanilamidopyrimidine is diazotized and coupled with 7-acetylamino-1-hydroxynaphthalene-3, 6-disulphonic acid to yield 4<;SP>;1<;/SP>;-(N-(2-pyrimidyl) sulphonamido) - 2 - azo - 7 - acetylamino - 1 - hydroxynaphthalene - 3, 6 - disulphonic acid and in (29) 2-(N<;SP>;4<;/SP>;-acetylsulphanilamido)-4- methyl - pyrimidine and (30) 2 - sulphanil - amido - 4 - methylpyrimidine are made by methods described above. This subjectmatter does not appear in the Specification as accepted.

    555,865. 磺胺基嘧啶。美国氰胺公司。1941年3月8日,编号3174和3175。公约日期,1940年3月1日和1940年10月15日。提供样本。[2类(iii)] p-取代苯磺酰氨基嘧啶通过将苯磺酰卤化物(例如,在对位由氨基或可通过水解、还原或与氨或胺(如酰氨基,硝基,卤素或偶氮基)反应转化的基团取代的氯化物)与氨基嘧啶反应制备。产品的一般公式如下,其中R是卤素,硝基,偶氮,氨基或取代氨基,例如烷基氨基,芳基氨基,芳基烷基氨基,酰胺基或单醛氨基,X是H,烷基基团或金属,Py是取代或未取代的嘧啶,n是小整数。单醛氨基化合物通过与单醛糖(例如半乳糖或葡萄糖)反应制备相应的氨基化合物而制备,最好在乙醇等溶剂中。在与苯磺酰卤化物反应过程中产生的游离氢卤酸通过在碱性介质中进行反应(例如水杨酸钠,三乙胺和吡啶)和指定的溶剂(例如二噁英,丙酮和苯)中除去。还描述了产品的碱金属或重金属(例如金,铅,铜和铁)盐。示例描述了通过上述方法制备以下化合物(1)5-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基) - 2,4-二羟基-,(2)5-(磺胺基)- 2,4-二羟基-,(3)5-(对-硝基苯磺胺基)- 2,4-二羟基-,(4)5-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基)-,(5)5-(磺胺基)-,(6)4-(对-硝基苯磺胺基)-,(7)和(9)4-(磺胺基)-,(8)4-(N <; SP>; 4 <;/ SP>; -乙酰-磺胺基)-,(10)2-(对-硝基苯-磺胺基)-,(11)和(13)2-(磺胺-氨基)-,(12)2-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基)-,(14)4-对-硝基苯磺胺基2-甲氧基-,(15)4-磺胺基-2-甲氧基-,(16)2-(对-硝基苯磺胺基)-4-甲氧基-,(17)2-磺胺基-4-甲氧基-,(18)2-(对-硝基苯磺胺基)-4,6-二甲基-,(19)2-磺胺基-4,6-二甲基-,(20)2-N <; SP>; 1 <;/ SP>; -甲基-磺胺基-,(21)4-对-氯苯-磺胺基-,(该嘧啶可以与氨或胺(例如甲胺,苯胺或苄胺)反应,生成相应的取代4-N <; SP>; 4 <;/ SP>; 嘧啶),(22)偶氮苯-对-,p <; SP>; 1 <;/ SP>; -(二-2-磺-氨基)-,(23)5-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基)-2-乙酰氨基-,(24)5-磺胺基-2-氨基,(25)5-(对-硝基苯磺胺基)-2-甲氧基-,(26)5-磺胺基-2. -甲氧基-,(27)2-(N <; SP>; 4 <;/ SP>; -乙酰磺胺基)-4-乙氧基-,(28)2-磺胺基-4-乙氧基,(29)2,5-二(对-硝基苯-磺胺基)-,(30)2,5-二磺胺基-,(31)2-(对-硝基苯-磺胺基)-5-氯-,(32)2-磺胺基-5-氯-,(33)2-磺胺基-的钠盐,(34)2-磺胺基-的铜盐,(35)2-磺胺基-的葡萄糖衍生物和(36)2-(N <; SP>; 4 <;/ SP>; -苄基磺胺基)-嘧啶。示例(35)和(36)涉及
  • [EN] COMPOUNDS AND METHODS FOR KINASE MODULATION, AND INDICATIONS THEREFOR<br/>[FR] COMPOSÉS ET PROCÉDÉS POUR LA MODULATION DES KINASES ET LEURS INDICATIONS
    申请人:PLEXXIKON INC
    公开号:WO2009012283A1
    公开(公告)日:2009-01-22
    Compounds of formula I active on protein kinases are described, as well as methods of using such compounds to treat diseases and conditions associated with aberrant activity of protein kinases. Formula (I) wherein Ar is optionally substituted heteroaryl; R2 is hydrogen, lower alkyl or halogen; U is selected from the group consisting of -S(O)2-, -C(X)-, -C(X)-N(R10)-, and -S(O)2-N(R10)-; R3 is optionally substituted lower alkyl, optionally substituted C3.6 cycloalkyl, optionally substituted heterocycloalkyl, optionally substituted aryl or optionally substituted heteroaryl; and wherein R1, R3, R4, m, L1, X R10 are as described herein.
    化合物的结构式I描述了对蛋白激酶具有活性的化合物,以及使用这些化合物治疗与蛋白激酶异常活性相关的疾病和症状的方法。其中Ar是可选择取代的杂芳基;R2是氢、低碳基或卤素;U选自由-S(O)2-、-C(X)-、-C(X)-N(R10)-和-S(O)2-N(R10)-组成的群;R3是可选择取代的低碳基、可选择取代的C3.6环烷基、可选择取代的杂环烷基、可选择取代的芳基或可选择取代的杂芳基;其中R1、R3、R4、m、L1、X和R10如本文所述。
  • 杂芳基胺类化合物的光化学合成方法
    申请人:天津凯莱英制药有限公司
    公开号:CN111732535B
    公开(公告)日:2021-03-12
    本发明提供了一种杂芳基胺类化合物的光化学合成方法。该光化学合成方法包括:步骤S1,将包括杂芳基硝基类化合物、溶剂、光催化剂的原料进行混合,得到混合物;步骤S2,将混合物在光照条件下进行光催化还原反应,得到含杂芳基胺类化合物的产物体系。本申请的上述光化学合成方法在光照条件下实现对各种不同的杂芳基硝基类化合物的光催化还原,获得了较高产率的杂芳基胺类化合物。光催化剂为现有常用的催化剂,其对设备没有严格要求,易于回收,降低了杂芳基胺类化合物的安全风险和催化剂成本。该光催化的整个反应过程无需加入任何金属试剂和还原剂,且反应的转化率较高,后处理简单易操作,因此,其更加安全环保。
  • Heterocyclic compounds and methods of use
    申请人:Chen Ning
    公开号:US20080227779A1
    公开(公告)日:2008-09-18
    The present invention comprises a new class of compounds capable of modulating the c-kit protein kinase and, accordingly, useful for treatment of c-kit mediated diseases including, without limitation, autoimmune disease, allergies, mastcytosis, mast cell related tumors and various fibrotic diseases. The compounds have a general Formula I wherein R 1-5 , X, Y and Z are defined herein. The invention further comprises pharmaceutical compositions, methods for treatment of c-kit mediated diseases, and intermediates and processes useful for the preparation of compounds of the invention.
    本发明包括一类新的化合物,能够调节c-kit蛋白激酶,并因此用于治疗c-kit介导的疾病,包括但不限于自身免疫性疾病、过敏、肥大细胞增生症、肥大细胞相关肿瘤和各种纤维化疾病。这些化合物具有一般的I式,其中R1-5,X,Y和Z在此定义。本发明还包括制药组合物,治疗c-kit介导的疾病的方法,以及制备本发明化合物的中间体和方法。
  • Amide Compound
    申请人:Matsumoto Takahiro
    公开号:US20080312226A1
    公开(公告)日:2008-12-18
    There is provided a FAAH inhibitor and a prophylactic or therapeutic agent for cerebrovascular disorders or sleep disorders comprising it. The prophylactic or therapeutic agent comprises a compound of the formula (I 0 ): R 1 —C—R 2 —R 3 —R 4 (I 0 ) wherein Z is oxygen or sulfur; R 1 is aryl which may be substituted, or a heterocyclic group which may be substituted; R 1a is a hydrogen atom, a hydrocarbon group which may be substituted, hydroxyl, etc.; R 2 is piperidin-1,4-diyl which may be substituted, or piperazin-1,4-diyl which may be substituted; R 3 is a group formed by eliminating two hydrogen atoms from a 5-membered aromatic heterocyclic group having 1 to 3 heteroatoms selected from nitrogen, oxygen and sulfur, which may be further substituted, —CO—, etc.; and R 4 is a hydrocarbon group which may be substituted, or a heterocyclic group which may be substituted; or a salt thereof.
    提供了一种FAAH抑制剂和预防或治疗脑血管疾病或睡眠障碍的药物,其中预防或治疗剂包括化合物(I0)的一种:R1-C-R2-R3-R4(I0),其中Z为氧或硫;R1为芳基,可以被取代,或者是可以被取代的杂环基;R1a为氢原子,可以被取代的碳氢基,羟基等;R2为可以被取代的哌啶-1,4-二基,或者可以被取代的哌嗪-1,4-二基;R3为从具有1到3个氮、氧和硫杂原子的5元芳香杂环基中消除两个氢原子形成的基团,可以进一步被取代,-CO-等;R4为可以被取代的碳氢基或者可以被取代的杂环基;或其盐。
查看更多

同类化合物

(N-(2-甲基丙-2-烯-1-基)乙烷-1,2-二胺) (4-(苄氧基)-2-(哌啶-1-基)吡啶咪丁-5-基)硼酸 (11-巯基十一烷基)-,,-三甲基溴化铵 鼠立死 鹿花菌素 鲸蜡醇硫酸酯DEA盐 鲸蜡硬脂基二甲基氯化铵 鲸蜡基胺氢氟酸盐 鲸蜡基二甲胺盐酸盐 高苯丙氨醇 高箱鲀毒素 高氯酸5-(二甲氨基)-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-2-甲基吡啶正离子 高氯酸2-氯-1-({(E)-[4-(二甲氨基)苯基]甲亚基}氨基)-6-甲基吡啶正离子 高氯酸2-(丙烯酰基氧基)-N,N,N-三甲基乙铵 马诺地尔 马来酸氢十八烷酯 马来酸噻吗洛尔EP杂质C 马来酸噻吗洛尔 马来酸倍他司汀 顺式环己烷-1,3-二胺盐酸盐 顺式氯化锆二乙腈 顺式吡咯烷-3,4-二醇盐酸盐 顺式双(3-甲氧基丙腈)二氯铂(II) 顺式3,4-二氟吡咯烷盐酸盐 顺式1-甲基环丙烷1,2-二腈 顺式-二氯-反式-二乙酸-氨-环己胺合铂 顺式-二抗坏血酸(外消旋-1,2-二氨基环己烷)铂(II)水合物 顺式-N,2-二甲基环己胺 顺式-4-甲氧基-环己胺盐酸盐 顺式-4-环己烯-1.2-二胺 顺式-4-氨基-2,2,2-三氟乙酸环己酯 顺式-2-甲基环己胺 顺式-2-(苯基氨基)环己醇 顺式-2-(氨基甲基)-1-苯基环丙烷羧酸盐酸盐 顺式-1,3-二氨基环戊烷 顺式-1,2-环戊烷二胺 顺式-1,2-环丁腈 顺式-1,2-双氨甲基环己烷 顺式--N,N'-二甲基-1,2-环己二胺 顺式-(R,S)-1,2-二氨基环己烷铂硫酸盐 顺式-(2-氨基-环戊基)-甲醇 顺-2-戊烯腈 顺-1,3-环己烷二胺 顺-1,3-双(氨甲基)环己烷 顺,顺-丙二腈 非那唑啉 靛酚钠盐 靛酚 霜霉威盐酸盐 霜脲氰